Citizens Reiterates Market Outperform on Immix Biopharma, Maintains $23 Price Target

Citizens analyst Reni J. Benjamin has reiterated a Market Outperform rating on Immix Biopharma (NASDAQ: IMMX) and has maintained a price target of $23 for the company's stock.